Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PAFSC’s First Committee Supports Approval of Second SGLT-2 Inhibitor Dapagliflozin
January 27, 2014
- FDA Bans Imports from Ranbaxy’s Toansa Plant, Daiichi Sankyo Promises Full Cooperation with FDA
January 27, 2014
- Health Minister Waits for Investigation Results on Novartis Involvement in “Sign” Study
January 27, 2014
- Comprehensive Strategy Proposal for “Japan NIH” Calls for Study on Legislation to Prevent Clinical Research Fraud by Autumn
January 27, 2014
- Expert Groups Call for Early Resumption of Active Recommendation for HPV Vaccines
January 27, 2014
- Regulatory Reform Council Eyes New Special System for Mixed Healthcare
January 24, 2014
- NHI Pricing of Generics Set to Undergo Major Revision to Help MHLW Achieve New Target; Promotion through Medical Fee Revision Also Planned
January 24, 2014
- DPP-4 Inhibitors, Remicade to Face Market Expansion Re-Pricing in FY2014 Revision
January 23, 2014
- Chuikyo OKs New NHI Drug Pricing Rules for FY2014 Revision
January 23, 2014
- Gov’t to Fully Implement Japan Version of “Compassionate Use” System in FY2015
January 23, 2014
- Final Decision on Active Recommendation for HPV Vaccines Will Be Made at Next Subcommittee Meeting: Minister
January 23, 2014
- Revised PAL to Ensure Drug Safety to Take Effect in Late November
January 22, 2014
- Novartis Sales Rep Involvement in Investigator-Initiated Trial “Extremely Regrettable”: Health Minister Tamura
January 22, 2014
- No Hand Raised for Additional Applicant Appeal for New Flu Vaccine Project, Quota for 25 Million People in Limbo
January 21, 2014
- HPV Vaccine Injection Site Pain Possible Cause of Chronic Pain: MHLW Subcommittees
January 21, 2014
- Prescribing of Torii’s Sublingual Cedar Pollinosis Treatment Cedartolen to be Restricted to Trained Doctors
January 21, 2014
- MHLW Approves Japan’s 1st SGLT-2 Inhibitor, Boehringer’s Anticancer Drug
January 20, 2014
- Public-Knowledge Based Applications Appropriate for Levonorgestrel, Methylprednisolone Sodium Succinate
January 20, 2014
- Mr Jo of EAD Criticizes Low Price Settlement Rates at Public Hospitals, Warns of Possible Reduction in Medical Fees
January 20, 2014
- PFSB Orders Distribution of Blue Letter on Bayer Yakuhin’s Dysmenorrhea Treatment YAZ Combination Tablets
January 20, 2014
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…